The FDA has issued a Boxed Warning for Veozah to inform users of the rare risk of serious liver damage, emphasizing the importance of regular blood tests.
Patients taking Veozah should consult their doctors about personal care plans and undergo regular liver function tests at specific intervals during the treatment.
The warning was implemented after a postmarketing report of liver injury symptoms emerged in a patient who had taken Veozah for about 40 days.
Symptoms of liver damage, such as fatigue, jaundice, and abdominal pain, should prompt immediate discontinuation of Veozah to prevent further injury.
Collection
[
|
...
]